EyePoint (EYPT) said Friday it filed a complaint in a Massachusetts court against Ocular Therapeutix (OCUL), alleging that Ocular made false or misleading claims about the company's lead eye-disease candidate, Duravyu.
The company said it is seeking to stop Ocular from making further false statements and to obtain a public retraction, according to a regulatory filing.
Ocular didn't immediately respond to MT Newswires' request for comment.
EyePoint shares were down 1.1% in premarket activity Monday, while Ocular fell 2.2%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments